Amgen (AMGN)
(Delayed Data from NSDQ)
$269.98 USD
+0.60 (0.22%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $270.08 +0.10 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
AMGN 269.98 +0.60(0.22%)
Will AMGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AMGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMGN
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
AMGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Why Amgen (AMGN) Outpaced the Stock Market Today
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
Other News for AMGN
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
Amgen announces imminent submission of MAA to EMA for teprotumumab
O'Keefe Stevens Advisory Q1 2024 Investor Letter
Diving Into Deciphera Pharmaceuticals
Catalyst Watch: Apple earnings, Viking IPO, Chinese EV deliveries and Russell indices' Rank Day